Manhattan West Asset Management LLC Cuts Stock Holdings in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Manhattan West Asset Management LLC decreased its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 28.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,187 shares of the company’s stock after selling 10,711 shares during the quarter. Manhattan West Asset Management LLC owned 0.30% of Global X Genomics & Biotechnology ETF worth $309,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in GNOM. International Assets Investment Management LLC bought a new position in Global X Genomics & Biotechnology ETF in the fourth quarter worth approximately $100,000. Centaurus Financial Inc. raised its position in shares of Global X Genomics & Biotechnology ETF by 14.6% during the 4th quarter. Centaurus Financial Inc. now owns 12,738 shares of the company’s stock valued at $147,000 after purchasing an additional 1,624 shares during the period. Insight Advisors LLC PA bought a new stake in shares of Global X Genomics & Biotechnology ETF during the 1st quarter valued at $152,000. James J. Burns & Company LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 35.6% during the 4th quarter. James J. Burns & Company LLC now owns 18,479 shares of the company’s stock valued at $214,000 after purchasing an additional 4,848 shares during the period. Finally, Capital Analysts LLC raised its position in shares of Global X Genomics & Biotechnology ETF by 8.9% during the 4th quarter. Capital Analysts LLC now owns 18,732 shares of the company’s stock valued at $217,000 after purchasing an additional 1,537 shares during the period. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM stock traded up $0.11 on Friday, hitting $11.72. 54,067 shares of the stock traded hands, compared to its average volume of 63,508. The firm has a market cap of $87.20 million, a price-to-earnings ratio of -5.01 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 52 week low of $8.63 and a 52 week high of $12.53. The firm has a 50 day simple moving average of $10.69 and a two-hundred day simple moving average of $10.90.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.